Literature DB >> 15571283

Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells.

O H Temmink1, E M Comijn, M Fukushima, G J Peters.   

Abstract

UNLABELLED: Trifluorothymidine (TFT) can be phosphorylated by thymidine kinase (TK) to TFTMP which can inhibit thymidylate synthase (TS), resulting in depletion of thymidine nucleotides. TFT can be degraded by thymidine phosphorylase (TP) which can be inhibited by thymidine phosphorylase inhibitor (TPI). Using the TS in situ Inhibition Assay (TSIA) FM3A breast cancer cells were exposed 4 h or 24 h to TFT and 5-Fluorouracil (5FU). TS activity reduced to 9% (0.1 microM TFT) and 58% (1 microM 5FU) after 4 h exposure and to 6% (TFT) and 21% (5FU) after 24 h exposure. TPI did not affect TS inhibition by TFT. FM3A cells lacking TK or TS activity (FM3A/TK-) were far less sensitive to TFT compared to FM3A cells.
CONCLUSION: TFT can be taken up and activated very rapidly by FM3A cancer cells, probably due to favourable TK enzyme properties, and TPI did not influence this.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15571283     DOI: 10.1081/NCN-200027707

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  13 in total

Review 1.  TAS-102, a novel antitumor agent: a review of the mechanism of action.

Authors:  Heinz-Josef Lenz; Sebastian Stintzing; Fotios Loupakis
Journal:  Cancer Treat Rev       Date:  2015-06-06       Impact factor: 12.111

2.  Trifluridine selectively inhibits cell growth and induces cell apoptosis of triple-negative breast cancer.

Authors:  Juan Li; Jie Liu; Riqi Wang; He Chen; Cui Li; Minggang Zhao; Fang He; Yaochun Wang; Peijun Liu
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

Review 3.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.

Authors:  Peter M Wilson; Peter V Danenberg; Patrick G Johnston; Heinz-Josef Lenz; Robert D Ladner
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675

Review 4.  Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.

Authors:  Godefridus J Peters
Journal:  Ther Adv Med Oncol       Date:  2015-11       Impact factor: 8.168

5.  Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.

Authors:  O H Temmink; E K Hoebe; K van der Born; S P Ackland; M Fukushima; G J Peters
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640

6.  Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.

Authors:  Kazuki Sakamoto; Tatsushi Yokogawa; Hiroyuki Ueno; Kei Oguchi; Hiromi Kazuno; Keiji Ishida; Nozomu Tanaka; Akiko Osada; Yukari Yamada; Hiroyuki Okabe; Kenichi Matsuo
Journal:  Int J Oncol       Date:  2015-04-20       Impact factor: 5.650

7.  CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil.

Authors:  Helena Almqvist; Hanna Axelsson; Rozbeh Jafari; Chen Dan; André Mateus; Martin Haraldsson; Andreas Larsson; Daniel Martinez Molina; Per Artursson; Thomas Lundbäck; Pär Nordlund
Journal:  Nat Commun       Date:  2016-03-24       Impact factor: 14.919

8.  Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine.

Authors:  Yuji Baba; Toshiya Tamura; Yoshihiko Satoh; Masamitsu Gotou; Hiroshi Sawada; Shunsuke Ebara; Kazunori Shibuya; Jumpei Soeda; Kazuhide Nakamura
Journal:  Mol Oncol       Date:  2017-05-30       Impact factor: 6.603

9.  Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression.

Authors:  Kazuaki Matsuoka; Fumio Nakagawa; Takashi Kobunai; Teiji Takechi
Journal:  Oncotarget       Date:  2018-02-05

10.  The antibodies against 5-bromo-2'-deoxyuridine specifically recognize trifluridine incorporated into DNA.

Authors:  Hiroyuki Kitao; Yosuke Morodomi; Shinichiro Niimi; Mamoru Kiniwa; Kazuhiko Shigeno; Kazuaki Matsuoka; Yuki Kataoka; Makoto Iimori; Eriko Tokunaga; Hiroshi Saeki; Eiji Oki; Yoshihiko Maehara
Journal:  Sci Rep       Date:  2016-05-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.